NEW WELLLINK
871634
VIBO
871245
MTD
835579
4
REFORMER
833030
5
Hunan Sundy Science And Technology
300515
HiCisco: Shareholder return plan for the next three years (2025-2027)
HiCisco: Announcement on the progress of establishing a subsidiary in the US
HiCisco: Announcement on the establishment of a subsidiary in the US
HiCisco: Announcement on obtaining an IND application acceptance letter for the innovative drug HSK41959 tablets
HiCisco: Legal Opinion of Beijing Zhonglun (Shenzhen) Law Firm on the 2025 First Extraordinary General Meeting of Shareholders of Hisilicon Pharmaceutical Group Co., Ltd.
HiCisco: Announcement of Resolutions of the 2025 First Extraordinary General Meeting of Shareholders
HiCisco: Announcement on the overall conclusion of fund-raising investment projects and follow-up arrangements for fund savings
HiCisco: Announcement on Additional Provisional Proposals and Supplementary Notices for the 2025 First Extraordinary General Meeting of Shareholders
HiCisco: Announcement on capital increase and related transactions for holding companies
HiCisco: Announcement on the Notice of Convening the First Extraordinary General Meeting of Shareholders in 2025
HiCisco: Announcement on the “Notice of Acceptance” of the IND Application for Two New Indications Obtaining the Innovative Drug HSK44459 Tablets
HiCisco: Announcement on obtaining industry support funds
HiCisco: Announcement on obtaining industry support funds
HiCisco: Announcement on the inclusion of cligabarin benzenesulfonate capsules and coglitin tablets in the national medical insurance catalogue
HiCisco: Announcement on Obtaining the “Notice of Acceptance” of the IND Application for the Innovative Drug HSK44459 Tablets
HiCisco: Announcement on Obtaining an IND Application Acceptance Notice for the Innovative Drug HSK39004 Inhalation Powder
HiCisco: Announcement on the progress of establishing wholly-owned subsidiaries in the British Virgin Islands and Cayman
HiCisco: Notice on Obtaining the “Notice of Acceptance” of the Application for Marketing of the Innovative Drug HSK21542 Injection for New Indications
HiCisco: Announcement on obtaining the “Notice of Acceptance” of the IND application for the innovative drug HSK46575 tablets
HiCisco: Announcement on the establishment of separate wholly-owned subsidiaries in the British Virgin Islands and Cayman